Patents by Inventor Natsuko Suginobe

Natsuko Suginobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
    Publication number: 20230183316
    Abstract: The present disclosure includes a pharmaceutical composition for treating a cancer in an HLA-A*02:07, HLA-A*03:01, HLA-B*15:01, or HLA-B*27:05-positive subject comprising a WT1-derived cancer antigen peptide or a peptide conjugate containing the peptide.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicants: SUMITOMO PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Masashi GOTO, Natsuko SUGINOBE, Megumi NAKAMURA
  • WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME
    Publication number: 20220211844
    Abstract: The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 7, 2022
    Inventors: Hitoshi Ban, Yosuke Takanashi, Masashi Goto, Natsuko Suginobe, Yusuke Imazaki, Yoshiko Iwata
  • TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION
    Publication number: 20220062421
    Abstract: The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1—O—R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2): or a group represented by the formula (3): —(CH2CH2O)mH (3), wherein m is an integer of 1-18.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 3, 2022
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Masayasu TANAKA, Kazumitsu YAMAMOTO, Hiroo MAEDA, Koichi SAITO, Natsuko SUGINOBE
  • COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR
    Publication number: 20180140691
    Abstract: The invention relates to a combination use of a WT1 antigen peptide or a pharmaceutically acceptable salt thereof and an immunomodulator for treating or preventing cancer.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 24, 2018
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Hideo TAKASU, Megumi NAKAMURA, Masashi GOTO, Natsuko SUGINOBE
  • TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION
    Publication number: 20150150975
    Abstract: The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1—O—R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2): or a group represented by the formula (3): —(CH2CH2O)mH (3), wherein m is an integer of 1-18.
    Type: Application
    Filed: July 2, 2013
    Publication date: June 4, 2015
    Inventors: Masayasu Tanaka, Kazumitsu Yamamoto, Hiroo Maeda, Koichi Saito, Natsuko Suginobe